Eric Smith, DO
Critical Care Medicine · Battle Creek, MINPI 1093195430
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Boehringer Ingelheim at 24.8% of the total. Reporting peaked in 2019 at $649 and has fallen 76.3% since, to $154 in 2025.
Across 109 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$580
- AstraZeneca$343
- GSK$297
- Abiomed$143
- Regeneron Healthcare Solutions, Inc.$134
- Mylan Specialty L.p.$112
- plus $730 from 20 others
What the payments were for
- Food & beverage$2,26097%
- Education$813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 27 | $580 |
| AstraZeneca | 22 | $343 |
| GSK | 19 | $297 |
| Abiomed | 1 | $143 |
| Regeneron Healthcare Solutions, Inc. | 4 | $134 |
| Mylan Specialty L.p. | 6 | $112 |
| Impulse Dynamics (USA) Inc. | 1 | $106 |
| Actelion Pharmaceuticals US, Inc. | 5 | $79 |
| Intuitive Surgical | 1 | $76 |
| Boston Scientific | 1 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Merck | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $33 |
| Insmed, Inc. | 2 | $32 |
| Pulmonx Corporation | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Gilead | 1 | $19 |
| Amgen | 1 | $17 |
| Bayer | 1 | $17 |
| Phadia US Inc. | 1 | $17 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,341 in reported general payments places this provider in the 85th percentile of 177 critical care medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 295 | $228,904 |
| OfevNintedanib Esylate | 12 | $203,947 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 77 | $53,436 |
| Spiriva RespimatTiotropium Bromide | 59 | $31,634 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 64 | $29,088 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $19,814 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $16,970 |
| Advair HfaFluticasone Propion/Salmeterol | 50 | $16,480 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $14,887 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $13,261 |
| Arnuity ElliptaFluticasone Furoate | 44 | $12,105 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $11,355 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 51 | $8,993 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 211 | $8,286 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 52 | $6,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $297 | $291,056458 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $580 | $276,024152 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $343 | $73,146144 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $54 | $4,46618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 critical care medicine providers in Michigan.
Other critical care medicine in Battle Creek
- Raakesh BhanBattle Creek$6K
- Angel Peralta-AvilaDetroit$147K
- Moumen AsbahiTroy$81K
- Mujahed AbbasLansing$28K
- Abdulrazak AlchakakiSouthfield$19K
- Narayana GandhamSaint Joseph$18K
- Sara MirzaAnn Arbor$12K
- Asker AsmiRiverview$11K
- Andrew EasowDearborn$10K
- Jeffery WiltGrand Rapids$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.